Apimeds Pharmaceuticals US Inc
APUS | AMEX
$2.94
$0.00 (+0.17%)
Nov 2, 2026, 9:42 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 20.04K | 20.04K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -20.04K | -20.04K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -19.24M | -15.62M | -11.91M | -5.15M | -3.6M | -1.37M | -1.28M | -1.56M | -1.36M | -962.78K | -747.44K | -254.55K | -150.39K | -122.57K | -66.19K |
Interest Income | 114.12K | 107.6K | 107.6K | 71.71K | 15.4K | 666 | 2.82K | 8.38K | 10.49K | 9.97K | 7.81K | 2.23K | n/a | n/a | n/a |
Pretax Income | -58.17M | -40.66M | -6M | -5.16M | -3.71M | -1.5M | -1.39M | -1.65M | -1.42M | -1.01M | -777.69K | -285.32K | -175.3K | -139.23K | -74.59K |
Net Income | -58.17M | -40.66M | -6M | -5.16M | -3.71M | -1.5M | -1.39M | -1.65M | -1.42M | -1.01M | -777.69K | -285.32K | -175.3K | -139.23K | -74.59K |
Selling & General & Admin | 24.51M | 21.2M | 10.28M | 3.88M | 2.95M | 1.37M | 1.28M | 1.53M | 1.34M | 914.79K | 648.89K | 122.44K | 15.29K | 9.9K | 4.07K |
Research & Development | 2.84M | 2.53M | 1.63M | 1.27M | 651.78K | n/a | n/a | 28.55K | 25.55K | 47.99K | 98.54K | 132.11K | 135.11K | 112.67K | 62.12K |
Other Expenses | -8.13M | -8.13M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 19.22M | 15.6M | 11.91M | 5.15M | 3.6M | 1.37M | 1.28M | 1.56M | 1.36M | 962.78K | 747.44K | 254.55K | 150.39K | 122.57K | 66.19K |
Interest Expense | 4.31M | 1.1M | 283.01K | 103.44K | 129.77K | 128.84K | 117.72K | 95.15K | 70.6K | 56.73K | 38.07K | 33K | 24.91K | 16.66K | 8.41K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 19.24M | 15.62M | 11.91M | 5.15M | 3.6M | 1.37M | 1.28M | 1.56M | 1.36M | 962.78K | 747.44K | 254.55K | 150.39K | 122.57K | 66.19K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.63M | 1.55M | 1.09M | 125.76K | 103.69K | 115.72K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K | 115.27K |
Shares Outstanding (Diluted) | 1.63M | 1.55M | 1.09M | 125.76K | 103.69K | 115.72K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K | 126.93K |
EPS (Basic) | -49.29 | -63.52 | -44.40 | -46.18 | -35.06 | -12.96 | -12.05 | -14.27 | -12.34 | -8.75 | -6.74 | -2.47 | -1.52 | -1.21 | -0.65 |
EPS (Diluted) | -49.29 | -63.52 | -44.40 | -45.94 | -34.56 | -12.10 | -10.96 | -12.97 | -11.22 | -7.96 | -6.13 | -2.25 | -1.38 | -1.10 | -0.59 |
EBITDA | -53.82M | -39.53M | -5.71M | -5.05M | -3.58M | -1.37M | -1.27M | -1.55M | -1.35M | -952.81K | -739.63K | -252.32K | -150.39K | -122.57K | -66.19K |
EBIT | -53.86M | -39.55M | -5.72M | -5.05M | -3.58M | -1.37M | -1.27M | -1.55M | -1.35M | -952.81K | -739.63K | -252.32K | -150.39K | -122.57K | -66.19K |
Depreciation & Amortization | 45.8K | 25.75K | 5.71K | 1.72K | 232 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove APUS